Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.  Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from submission, for a target action date of July 30, 2012.

Related posts:

1. ASCO 2011… gli abstract (prima parte).
2. Hedgehog inibitori parte 1: Vismodegib in approvazione FDA.
3. ASCO 2011… gli abstract (seconda parte)
4. CBRX: approvazione di Prochieve e lo scandalo Makena.